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A B S T R A C T
Objective: To evaluate risk factors for multidrug-resistant tuberculosis (MDR-TB) in an
urban setting of Pakistan.
Design and methods: In this multicenter case–control study, patients aged 15 years old or
older with sputum culture and sensitivity (C/S) diagnosed with pulmonary MDR-TB were
defined as cases, whereas patients aged 15 years old or older with sputum C/S diagnosed
and susceptible to pulmonary TB were regarded as controls. Fifty cases and 75 controls
were enrolled from three tertiary-care hospitals in Karachi.
Results: Multivariable logistic regression models showed that cases were more likely to have
had a TB patient in the house prior to the diagnosis of MDR-TB (adjusted odds ratio
[ORadj] = 3.1, 95% confidence interval [CI]: 1.2, 8.3) or had a history of prior TB treatment
(ORadj = 4.2, 95% CI: 1.1, 15.4). Furthermore, cases compared with controls tended to be male
(ORadj = 3.6, 95% CI: 1.4, 9.7), 15–25 years of age (ORadj = 3.7, 95% CI: 1.2, 11.3), of Sindhi ethnic-
ity (adjusted OR = 9.1, 95% CI: 1.9, 43.4) or with low educational attainment (ORadj OR = 5.5,
95% CI: 1.7–17.6, for no formal schooling; ORadj = 3.8, 95% CI: 1.1–14.1, 1 for 1–5 school years).
Conclusions: A TB patient in the house or a history of prior TB treatment was strongly associ-
ated with MDR-TB in this study. Furthermore, younger age, male gender, Sindhi ethnicity and
poor educational attainment entailed a high risk for MDR-TB. Targeted educational interven-
tion for patients and their contacts may minimize the noncompliance with prescribed TB
treatment and lessen MDR-TB magnitude in settings like Karachi.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) has been defined
as the resistance of Mycobacterium tuberculosis strains to both
isoniazid (INH) and rifampicin (RMP) with or without simulta-
neous resistance to other drugs [1]. MDR-TB poses a therapeu-
tic and infection control challenge with significantly higher
rates of morbidity and mortality [2,3]. Also, it has substantial
economic implications of high treatment cost which is nearly
100 times the cost of treating a susceptible TB case [4].
A worldwide assessment in 35 countries revealed an over-
all prevalence of MDR-TB as 12.6% for single-drug resistance
(range, 2.3–42.4%) and 2.2% for multidrug resistance (range,
0–22.1%) in all the countries surveyed [5]. About 50 million
2212-5531/$ - see front matter  2012 Asian-African Society for Mycobacteriology. All rights reserved.
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people were infected with multidrug resistant M. tuberculosis
strains globally [6], and they account for 14% of the world’s to-
tal TB cases [7]. In Pakistan an estimated 10–14% of TB pa-
tients are suffering from MDR-TB [8].
Spontaneous mutations leading to drug resistance occur
rarely in M. tuberculosis [9]. Mainly, MDR-TB results from treat-
ment that is inadequate, often because of an irregular drug
supply, inappropriate regimens, or poor compliance [5]. The
other known risk factors for MDR-TB include contact with a
drug-resistant TB patient [10], younger age [11], lower socio-
economic status, homelessness [12], male gender with less
than normal body mass index [13], and human immunodefi-
ciency virus (HIV) infection [10,11]. However, only limited data
on the role of these factors in perpetuating MDR-TB in Paki-
stan and other countries in the region are available. There-
fore, the purpose of this case–control study was to identify
risk factors for MDR-TB in an urban setting of Pakistan.
Knowledge of such factors that may have been contributing
in MDR-TB in this and similar settings may be used to design
an effective TB control program.
Patients and methods
Study setting
Karachi is a major industrial and trade center of Pakistan. It has
an estimated population of 9.8 million, which is largely multi-
ethnic in character. Health services are provided both by public
and private health care facilities in Karachi. Private sector lar-
gely consists of private practitioners, hospitals and teaching
institutions, while the public sector is comprised of govern-
ment hospitals and dispensaries. For this study, cases and con-
trols were enrolled from three tertiary care health facilities of
Karachi, namely, Aga Khan University Hospital, Jinnah Post-
graduate Medical Center, and Ojha Institute of Chest Diseases.
Definitions and selection of cases and controls
In this study, a case was considered a patient of either gender,
aged 15 years old or older, diagnosed with culture-confirmed
MDR-TB and M. tuberculosis strain resistant to at least INH
and RMP (two first-line anti-TB dugs) [1,13,14]. The control
was a patient of either gender, aged 15 years old or order,
diagnosed with culture-confirmed non-MDR-TB and M. tuber-
culosis strain sensitive to first-line (INH, RMP, pyrazinamide,
ethambutol and streptomycin) anti-TB drugs [15]. Between
January 1, 2000, and February 28, 2002, eligible cases and con-
trols were identified through the records or in-patients of the
three tertiary-care hospitals and were invited to participate in
the study. Cases and controls unable to provide an interview
owing to problems with speech, hearing or very poor general
state of health were excluded.
Data collection
A structured and pre-tested questionnaire was administered
to both cases and controls. The questionnaire comprised
questions on socio-demographic characteristics, BCG vacci-
nation, and history of prior TB treatment. It also included
questions on the presence of any TB patients in the family
or other possible sources of contact with TB patient(s), cur-
rent therapy for TB if any, and compliance with past and pres-
ent TB therapy. Two data collectors (one male and one female)
and the principal author constituted the data collection team.
Both the data collectors were fluent in Urdu and Sindhi – the
two main locally spoken dialects – had over 12 years of formal
schooling, and had previous experience in carrying out ques-
tionnaire-based interviews. Postal addresses and, where
available, telephone numbers were obtained from medical re-
cords. Subjects were contacted at given addresses, and face-
to-face interviews were conducted. Eligible subjects available
during data collection period as in-patients were interviewed
in the respective wards of the three hospitals.
Data analysis
Data were managed using EPI-INFO version 6.04 (Centers for
Disease Control and Prevention, Atlanta, GA, USA) and ana-
lyzed using SPSS version 10 (Chicago, IL, USA). Descriptive
statistics were computed for independent variables and com-
pared between cases and controls using v2 test or Student’s
t-test as appropriate. Unadjusted association of each
independent variable with the outcome variable (case/control
status) was evaluated using univariable logistic regression
analyses. Variables significantly (P < 0.25) associated with
the outcome were considered for inclusion in a multivariable
logistic regression model [16]. Adjusted odds ratio (ORadj) and
unadjusted OR for history of prior TB treatment (primary
exposure of interest) were compared in the presence and ab-
sence of other variables respectively. If there was an absolute
difference of 10% or more in ORadj and unadjusted OR for his-
tory of prior TB treatment in the presence and absence of a gi-
ven variable, it was retained in the multivariable logistic
regression model. After developing a main effect model, bio-
logically meaningful interaction terms were assessed for their
statistical significance. The final model was evaluated by the
Hosmer–Lemeshow goodness-of-fit test [16]. An informed
consent was always requested from eligible subjects, and
those consenting to participate in the study were interviewed.
The study was approved by the institutional ethics review
committee.
Results
Fifty cases and 75 controls were enrolled in this study. The
mean (SD) age (years) of cases and controls was 31.5 (12.0)
and 44.0 (19.6), respectively. The proportions of males among
cases and controls were 50% and 32%, respectively. Com-
monly spoken dialect was Sindhi in cases (34%) and Urdu in
controls (37%). Higher proportion of cases (38%) than controls
(19%) had no formal schooling. More cases (64%) than controls
(60%) were married and a higher proportion of cases (52%)
than controls (27%) reported a monthly income less than
4000 rupees. Also, a higher proportion of cases (60%) than
controls (32%) tended to live in a household size of seven or
more persons (Table 1).
Smoking history was nearly similar in cases and controls,
whereas a higher proportion of cases (30%) than controls
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(13%) were BCG un-vaccinated. More cases (44%) than con-
trols (23%) reportedly had a TB patient at home. Furthermore,
90% (45/50) of the cases and 73% (55/75) of the controls report-
edly had a history of prior TB treatment. Among those who re-
ported a history of prior TB treatment, 42% (19/45) of the cases
and 9% (5/55) of the controls reported discontinuation of past
TB treatment (Table 2). Among first-line anti-TB drugs, all 50
(100%) cases were resistant to INH and RMP. Also, 18% of the
cases were resistant to streptomycin, 12% to ethambutol
and 18% to pyrazinamide (Fig. 1).
Logistic regression analysis
Unadjusted logistic regression analyses showed that age, gen-
der, ethnicity, education, total monthly household income,
household size, BCG vaccination status, presence of a TB pa-
tient in the household, history of prior TB treatment, and re-
ported history of prior TB treatment discontinuation were
significantly (P < 0.05) associated with MDR-TB status (Tables
1 and 2). The final multivariable logistic regression model re-
vealed that cases compared with controls were significantly
more likely to have had a TB patient in the house (ORadj = 3.1,
95% CI: 1.2–8.3) or had a history of prior TB treatment (OR-
adj = 4.2, 95% CI: 1.1–15.4). Of demographic factors signifi-
cantly associated with MDR-TB status were age (ORadj = 3.7;
95% CI: 1.2–11.3 for 15–25 years old), male gender (ORadj = 3.6;
95% CI: 1.4–9.7), Sindhi ethnicity (ORadj = 9.1; 95% CI: 1.9–43.4),
and low educational attainment (ORadj OR = 5.5, 95% CI: 1.7–
17.6 for no formal school years; ORadj = 3.8, 95% CI: 1.1–14.1
for 1–5 school years). Hosmer–Lemeshow goodness-of-fit sta-
tistic for the final multivariable logistic regression model was
5.8 (P = 0.7) (Table 3).
Discussion
The choice of using case–control design was based on earlier
recommendations to the study on the epidemiology of MDR-
TB [10]. Also, the standard definitions of MDR-TB and drug
susceptible TB were used to select cases and controls respec-
tively during a comparable time frame [14,17,18].
In this study, MDR-TB cases tended to report a history of
prior TB treatment more often than controls or reportedly
had a TB patient in the house. Furthermore, patients with pul-
monary MDR-TB compared with those with pulmonary sus-
ceptible TB tended to be younger (15–25 years old), of male
gender, Sindhi ethnicity, and had only five or less years of for-
mal schooling.
Consistent with the results of previous studies both in
developed and developing countries, this study showed that
a history of prior TB treatment was a significant predictor of
MDR-TB [19,20]. Acquired drug resistance of M. tuberculosis
to anti-TB drugs may occur, when there is a history of incom-
Table 1 – Distribution and univariable logistic regression analysis of demographic factors associated with multidrug-resistant
tuberculosis in a case–control study, Karachi, Pakistan.
Variable Cases, n (%) (N = 50) Controls, n (%) (N = 75) Crude OR 95% CI
Age (completed years)
15–25 19 (38) 14 (19) 1.9 1.4–8.0
26–32 13 (26) 17 (22) 3.3 0.8–4.6
>32 18 (36) 44 (59) 1.0 –
Gender
Male 25 (50) 24 (32) 2.5 1.2–5.3
Female 25 (50) 51 (68) 1.0 –
Mother tongue (ethnicity)
Punjabi 7 (14) 10 (13) 2.2 0.6–7.4
Sindhi 17 (34) 5 (7) 10.6 3.0–39.0
Others# 17 (34) 32 (43) 1.7 0.6–4.3
Urdu 9 (18) 28 (37) 1.0 –
Education (years of formal schooling)
Nil 19 (38.0) 14 (19) 3.4 1.5–7.9
1–5 13 (26.0) 17 (23) 2.6 1.0–7.2
>5 18 (36.0) 44 (59) 1.0 –
Marital status
Married 32 (64) 45 (60) 1.2 0.6–2.5
Single 18 (36) 30 (40) 1.0 –
Household income (rupees/month)
<4000 22 (52) 14 (27) 3.0 1.3–7.1
P4000 20 (48) 38 (73) 1.0 –
Household size
>10 8 (16) 10 (13) 7.2 1.0–10.7
7–10 22 (44) 14 (19) 14.1 2.8–70.6
4–6 18 (36) 33 (44) 4.9 1.0–23.6
1–3 2 (4) 18 (24) 1.0 –
OR = odds ratio; CI = confidence interval; # Includes Pushto, Balochi, Gujarati, Parsi.
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plete or inappropriate TB treatment regimens for at least
1 month [2,21–23]. Therefore, MDR-TB patients in this study
might have experienced similar conditions.
The presence of a TB patient in the household was used as
a surrogate variable for a possible source for acquisition of
MDR M. tuberculosis infection through household contact with
a MDR-TB patient. Previous studies of contact tracing of MDR-
TB patients have shown a clear link between prior exposure
to a patient with infectious TB resistant to numerous drugs
and subsequent development of TB with similar resistance
patterns [17,18,24]. Sensitivity patterns against anti-TB drugs
for such household members could not be ascertained owing
to logistic reasons and was beyond the scope of this study. Fu-
ture studies may look at this aspect.
Younger patients (15–25 years old) were more likely to suf-
fer from MDR-TB than the patients in other age groups in this
study. The association of age and MDR-TB has not been con-
sistently identified [11]. MDR-TB in younger age groups have
previously been reported [25] or older age (45–64 years) groups
[26], but some other studies did not find this association
[27,28]. This variation in relationship of age with MDR-TB
may be a reflection of localized socio-economic factors re-
lated to exposure opportunity and development of MDR-TB.
In this study, cases were more likely to be male than con-
trols. Significant preponderance of males towards MDR-TB
has also been previously demonstrated [17,29]. Men are con-
sidered relatively more unconcerned than females regarding
regular intake of medication, and this fact may have led to
more males having MDR-TB in this study. Furthermore, it
has been hypothesized that TB being more frequent among
men may reflect gender differences in risk for M. tuberculosis
infection or progression of TB [4]; however, such reasons for
MDR-TB being more common among males have not been
established and need further investigation.
Cases in this study tended to have five or less years of
schooling. Patients with no or little education reportedly were
more likely to default or non-comply with anti-TB treatments
in Korea and elsewhere, which might have led to the develop-
ment of acquired MDR-TB [30,31]. Similar patients’ attitude
may explain the association of low education attainment
and increased likelihood of MDR-TB in this study.
Sindhi ethnicity was associated with increased odds of
MDR-TB in this study. It has been shown that being an Asian
was associated with an increased risk of developing MDR-TB
regardless of living environment [11,17]. To substantiate this
finding, there is a need to further explore this association
with regard to diverse lifestyles and practices among different
ethnicities in Pakistan.
Table 2 – Distribution and univariable logistic regression analysis of putative risk factors associated with multidrug-resistant
tuberculosis in a case–control study, Karachi, Pakistan.
Variable Cases, n (%) (N = 50) Controls, n (%) (N = 75) Crude OR 95% CI
Smoking history
Ever smoked 15 (30) 21 (28) 1.1 0.5–2.4
Never smoked 35 (70) 54 (72) 1.0 –
BCG vaccination status
Un-vaccinated 15 (30) 10 (13) 2.8 1.1–6.8
Vaccinated 35 (70) 65 (87) 1.0 –
Presence of TB patient in household
Yes 22 (44) 17 (23) 2.7 1.2–5.8
No 28 (56) 58 (77) 1.0 –
History of prior TB treatment
Yes 45 (90) 55 (73) 3.3 1.1–9.4
No 5 (10) 20 (27) 1.0 –
Compliance to prior TB treatment
Quit medication 19 (38) 5 (7) 15.2 3.2–77.5
Didn’t quit medication 26 (52) 50 (67) 2.1 0.7–7.9
No past medication 5 (10) 20 (26) 1.0 –
OR = odds ratio; CI = confidence interval.
Fig. 1 – Drug resistance of Mycobacterium tuberculosis strains
isolated from multi-drug resistant tuberculosis cases in
Karachi, Pakistan 2001–2002 (N = 50).
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Some limitations in this study are worth mentioning: First,
potential recall bias is an inherent characteristic of a case–
control design [32], therefore, some recall bias might have crept
in while responding to a history of prior anti-TB treatment.
However, misclassification of exposures of interest – if indeed
it has occurred – was expected to be non-differential. Secondly,
it could not empirically be determined whether MDR-TB cases
in this study have had primary drug resistance or were ac-
quired through inadequate and/or incomplete prior TB treat-
ment. However, it is believed that MDR M. tuberculosis strains
have relatively low transmissibility [9]. Future studies may look
at this aspect of study design. Thirdly, this study was somewhat
under-powered; therefore, several established risk factors –
notably smoking, monthly income, household size, etc. –
turned out to be non-significantly related with MDR-TB status.
This issue of limited sample size needs to be addressed in any
such future evaluation. Finally, this study was carried out in ur-
ban settings; therefore, generalization of these results to a pop-
ulation segment residing in rural areas wherein over 60% of the
country’s population lives needs to be done with care.
In conclusion, this study showed that a history of prior TB
treatment, the presence of a TB patient in the house, younger
age, male gender, Sindhi ethnicity and low educational attain-
ment were all associated with MDR-TB in an urban setting of
Pakistan. Targeted educational intervention at patients with
identified characteristics and their household contacts may
minimize the noncompliance with the prescribed treatment
and thereby lower the magnitude of MDR-TB in this and
similar settings. Future studies to evaluate the public health
impact of such educational intervention on the burden of
MDR-TB are indicated.
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